{
    "source": {
        "id": "axios",
        "name": "Axios"
    },
    "author": "Sam Baker",
    "title": "Experimental coronavirus drug sees promising yet unofficial results",
    "description": "Coronavirus patients in a Chicago hospital recovered quickly after receiving remdesivir, a drug made by Gilead Sciences, according to STAT. It\u2019s the latest positive sign for a drug that\u2019s already seen as one of the most promising potential treatments for the \u2026",
    "url": "https://www.axios.com/coronavirus-treatment-remdesivir-patients-recover-b54793a5-f883-49fb-a874-bd32a9648040.html",
    "urlToImage": "https://images.axios.com/N_1gKY8l4oWldtnZDgh0oTmIBfE=/2020/04/16/1587077675976.jpg",
    "publishedAt": "2020-04-16T22:56:15Z",
    "content": "It's well-known that the coronavirus targets the lungs, but evidence suggests that the virus may also cause heart inflammation, acute kidney disease, neurological problems, blood clots, intestinal damage and liver issues, the Washington Post reports.\r\nWhy it \u2026 [+172 chars]"
}